Guggenheim raised the firm’s price target on Johnson & Johnson to $227 from $206 and keeps a Buy rating on the shares. After reviewing the firm’s J&J company model, the analyst sees “multiple drivers of additional upside” heading into 2026, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- 3 Best Dividend Aristocrat Stocks to Buy Now, 12/4/2025
- FDA shift in drug study requirements sends trial runners lower
- FDA to reduce number of trials required for drug approvals, STAT reports
- Is AstraZeneca’s Stock (AZN) a Good Investment Right Now?
- Top drug regulator Richard Pazdur preparing to exit FDA, STAT News reports